Acta dermatovenerologica Croatica : ADC
-
Dear Editor, Tattooing is a global and ancient practice that has endured until the present day. It was originally used to indicate religious beliefs, tribal affiliation, loyalty to a leader, or had a therapeutic function. Adverse reactions from tattooing are common, and cutaneous reactions to red pigment have been widely reported (1,2). ⋯ Tattooists should use a checklist and informed consent to screen people with such potential risk factors. Furthermore, it is necessary to perform additional studies concerning ink and pigment components, with the aim of systemically characterizing the substances used in tattoos. Lastly, as emphasized by our case, patients at risk should referred to the dermatologist not only before getting a new tattoo but also in case of color changes in a pre-existing tattoo.
-
Acta Dermatovenerol Croat · Mar 2019
Biography Historical ArticleIN MEMORIAM Professor ZDRAVKO PERIŠ, MD, PhD (1927-2018).
On December 4, 2018, death took from us and his family Professor Zdravko Periš, Croatia's oldest and most renowned living dermatovenerologist, after a long and severe illness. Professor Periš was born in Vis in 1927, after which the family moved to Ljubljana, Slovenia, where he finished primary and secondary school. He attended the University of Ljubljana Faculty of Medicine but spent the last semesters in Zagreb and graduated from the Zagreb University Medical School in 1955. ⋯ In his private life, he loved his family above all: his wife Jelka who lived with him for more than 60 years, his son Zdravko and his granddaughter Nika. It was my great privilege and fortune that I had the opportunity to work with Professor Periš for a few years, and we always remained on friendly terms after his retirement. We shall always remember his kindness and respect his mastery in the care and treatment of his patients.
-
Acta Dermatovenerol Croat · Dec 2018
Historical ArticleFrom the History of the Croatian Dermatovenereological Society - The Croatian Medical Association and an Overview of Important Information Regarding the Journal Acta Dermatovenerologica Croatica.
Everything included in this overview is a list of facts without analyses, which makes this a purely factual overview. The circumstances of the preparation for the foundation of the Croatian Dermatovenereological Society - the Croatian Medical Association (hereafter CDS-CMA) and the journal Acta Dermatovenerologica Croatica (hereafter ADC) Geopolitical changes in former Yugoslavia following 1990 and the Homeland War (1991-1995) led to new circumstances in almost all areas of social activity and the need for a restructuring and further development of professional physicians associations in our Homeland. In such new conditions, it was necessary to appropriately organize the professional work of our dermatovenerologists with the aim of founding and maintaining their professional ties to each other and to our colleagues abroad. ⋯ It is unnecessary to emphasize the importance of the fact that we have such a respectable journal in our Homeland. NOTE: The honorable duty of preparing this text was entrusted to me by the president of the CDVS-CMA, Prof. Mirna Šitum, PhD, at the meeting of the Executive Board of CDVS-CMA held on the 16th of April 2012 (for the purposes of an oral presentation of this data at the 3rd Croatian Congress of Psychodermatology with international participation, Split, 4-7 October, 2012, and again at the meeting of the Executive Board of CDVS-CMA, held on the 7th of June 2013 for the purposes of the web page of CDVS-CMA).
-
Acta Dermatovenerol Croat · Dec 2018
Microsatellite Instability Predicts Response to Anti-PD1 Immunotherapy in Metastatic Melanoma.
Dear Editor, Immune-checkpoint blockade is a type of passive immunotherapy aimed at enhancing preexisting anti-tumor responses of the organism, blocking self-tolerance molecular interactions between T-lymphocytes and neoplastic cells (1,2). Despite a significant increase in progression-free survival, a large proportion of patients affected by metastatic melanoma do not show durable responses even after appropriate diagnostic categorization and shared therapeutic choices (3-9). Therefore, predictive biomarkers of clinical response are urgently needed, and predictive immunohistochemistry (IHC) meets these requirements. ⋯ S. Food and Drug Administration has approved the use of pembrolizumab in 2017 for unresectable or metastatic solid tumors with MMR deficiency (14). In conclusion, dMMR melanoma seems to be a particular subset of disease that can be identified with high sensibility and specificity by predictive IHC as a complete loss of one or more DNA MMR proteins and that deserves targeted therapy.
-
Acta Dermatovenerol Croat · Oct 2018
EditorialNEW IMPACT FACTOR FOR ACTA DERMATOVENEROLOGICA CROATICA.
June brought us good news: based on the new impact factors for 2017 published by Clarivate analytics (previously Thompson-Reuters), Acta Dermatovenerologica Croatica (ADC) has reached one of the milestones - an impact factor (IF) of 1.054. After entering Excerpta Medica in 1994, Index Medicus / Medline in 2001, and the Science Citation Index Expanded in 2007, we tried our best to improve the visibility and presence of our Journal and to increase its impact factor. From 2009 to 2015, the IF of ADC was between 0.272 and 0.581, with some ups and downs. ⋯ We still try to publish case reports although we know that they do not improve impact factor, but our position is that case reports are the best opportunity for the future of our dermatovenereology - our residents - to publish their first article. Acta Dermatovenerologica Croatica is proud to be the official journal of the Croatian Dermatovenereological Society of the Croatian Medical Association and also supported by the Croatian Ministry of Science, which gives us the freedom to provide balanced content that includes some case reports, and all of it free of charge, something no longer as common in many journals in recent years. This new impact factor is a great encouragement for the whole Editorial Board to work towards improving our Journal and reaching next milestone - entering a more prestigious index and increasing our impact factor further.